ValuEngine downgraded shares of Teligent, Inc. (NASDAQ:TLGT) from a hold rating to a sell rating in a report released on Tuesday morning.

A number of other equities analysts have also weighed in on TLGT. Zacks Investment Research lowered shares of Teligent from a hold rating to a sell rating in a research report on Thursday, July 6th. Deutsche Bank AG reiterated a hold rating and set a $9.00 target price (up previously from $8.00) on shares of Teligent in a research report on Monday, July 17th. Finally, BidaskClub lowered shares of Teligent from a hold rating to a sell rating in a research report on Monday, July 24th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $9.00.

Shares of Teligent (NASDAQ:TLGT) traded down 2.29% during mid-day trading on Tuesday, reaching $7.69. 512,745 shares of the company’s stock traded hands. Teligent has a 12-month low of $5.75 and a 12-month high of $9.54. The firm has a 50-day moving average of $8.78 and a 200 day moving average of $8.00. The company’s market cap is $409.31 million.

ILLEGAL ACTIVITY WARNING: “ValuEngine Downgrades Teligent, Inc. (TLGT) to Sell” was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/valuengine-downgrades-teligent-inc-tlgt-to-sell/1461583.html.

Institutional investors have recently modified their holdings of the company. State Street Corp raised its position in shares of Teligent by 11.7% in the fourth quarter. State Street Corp now owns 647,583 shares of the company’s stock worth $4,280,000 after buying an additional 67,935 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its position in shares of Teligent by 10.1% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 38,332 shares of the company’s stock worth $253,000 after buying an additional 3,512 shares in the last quarter. Guggenheim Capital LLC raised its position in shares of Teligent by 22.9% in the fourth quarter. Guggenheim Capital LLC now owns 207,040 shares of the company’s stock worth $1,369,000 after buying an additional 38,594 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Teligent by 1.0% in the fourth quarter. Teachers Advisors LLC now owns 65,454 shares of the company’s stock worth $433,000 after buying an additional 648 shares in the last quarter. Finally, Cutler Group LP raised its position in shares of Teligent by 217.6% in the first quarter. Cutler Group LP now owns 23,923 shares of the company’s stock worth $186,000 after buying an additional 16,391 shares in the last quarter. Hedge funds and other institutional investors own 62.12% of the company’s stock.

About Teligent

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.